Regeneron

Corporate brand

Regeneron is a leading American biotechnology company that discovers, develops, and commercializes medicines for serious diseases, including eye conditions, cancer, and inflammatory diseases.

Last updated November 3, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, the company has grown into one of the largest biotech firms in the world, with a portfolio of approved medicines and a robust pipeline. Regeneron is known for its VelocImmune technology, which uses genetically humanized mice to produce fully human monoclonal antibodies. This platform has yielded blockbuster drugs such as Eylea (aflibercept) for eye diseases, Dupixent (dupilumab) for atopic dermatitis and asthma, and Libtayo (cemiplimab) for certain cancers. The company also markets Praluent (alirocumab) for high cholesterol and Kevzara (sarilumab) for rheumatoid arthritis. Regeneron has collaborations with major pharmaceutical companies, including Bayer and Sanofi, and has expanded into areas such as COVID-19 antibody cocktails and gene editing through its Regeneron Genetics Center. The company is publicly traded on NASDAQ under the ticker REGN and is a component of the S&P 500. With a strong focus on R&D, Regeneron invests billions annually in research and has been recognized for its innovative culture and scientific breakthroughs.

History

Regeneron Pharmaceuticals was founded in 1988 by Leonard Schleifer, a neurologist, and George Yancopoulos, a scientist, in Tarrytown, New York. The company initially focused on developing treatments for neurodegenerative diseases. In the 1990s, Regeneron shifted its focus to antibody discovery and developed its proprietary VelocImmune technology, which uses genetically engineered mice to produce fully human monoclonal antibodies. This platform became the foundation for many of its later drugs. In 1991, Regeneron went public. The company's first major product, Arcalyst (rilonacept), was approved in 2008 for cryopyrin-associated periodic syndromes. In 2011, Eylea (aflibercept) was approved for wet age-related macular degeneration, becoming a blockbuster and a major revenue driver. In 2017, Dupixent (dupilumab) was approved for atopic dermatitis, followed by approvals for asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Regeneron has also developed Libtayo (cemiplimab) for cutaneous squamous cell carcinoma and basal cell carcinoma, and Praluent (alirocumab) for high cholesterol. The company has collaborations with Sanofi, Bayer, and others. In 2020, Regeneron received emergency use authorization for REGEN-COV, an antibody cocktail for COVID-19. Regeneron continues to invest heavily in R&D, with a focus on genetics, neuroscience, and immuno-oncology.

2020
REGEN-COV authorized for emergency use for COVID-19.
2017
Dupixent (dupilumab) approved for atopic dermatitis.
2011
Eylea (aflibercept) approved for wet AMD.
2008
Arcalyst (rilonacept) approved by FDA.
1991
Regeneron becomes a public company.
1988
Regeneron founded by Leonard Schleifer and George Yancopoulos.

Products and positioning

Regeneron positions itself as a science-driven biotech company focused on translating breakthrough science into medicines for serious diseases, with a strong emphasis on proprietary technology platforms and collaborations.

Eylea
Treatment for wet age-related macular degeneration, diabetic retinopathy, and other eye conditions.
Dupixent
Treatment for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
Libtayo
Treatment for cutaneous squamous cell carcinoma and basal cell carcinoma.
Praluent
Treatment for high cholesterol.
Kevzara
Treatment for rheumatoid arthritis.

Controversies

2021
Amgen files Supreme Court petition in patent dispute
Amgen Inc. and its subsidiaries filed a petition for certiorari with the U.S. Supreme Court against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC. The petition concerns the written-description requirement for patents and the level of detail required.
Source
2021
Humana sues Regeneron over alleged Eylea pricing scheme
Humana filed suit against Regeneron, alleging that Regeneron and the Chronic Disease Foundation engaged in a scheme involving Eylea that defrauded Medicare and its contracted payors. The complaint alleged that Regeneron inflated Eylea's price and provided illegal kickbacks to the foundation; these are allegations, not a stated court finding.
Source
2021
Shareholder advisers criticize Regeneron executive payouts
Shareholder advisory groups Glass Lewis and Institutional Shareholder Services criticized Regeneron’s upfront executive stock awards as excessive and questioned whether they were in shareholders’ best interests. The article also reports substantial shareholder opposition to the company’s executive payouts in recent years.
Source
2020
DOJ files civil lawsuit against Regeneron over patient charity payments
The US Department of Justice filed a civil lawsuit against Regeneron, alleging that the company illegally paid a patient group to cover costs for Medicare patients receiving its Eylea treatment. Regeneron said the allegations had no merit and that it would defend the case.
Source
2020
Sanofi stops Kevzara COVID-19 clinical trials
Sanofi stopped clinical trials of Kevzara for COVID-19 after tests found adverse effects, including pneumonia and death in some patients. The company said it no longer planned further COVID-19 clinical studies of the drug. The event was reported in connection with Regeneron, the brand associated with Kevzara.
Source
2020
U.S. sues Regeneron over alleged Eylea kickbacks
The U.S. Justice Department sued Regeneron, accusing the company of making kickback payments related to Eylea through a copay foundation. The case alleges false claims and seeks treble damages; the allegations are not established as findings in this article.
Source

Unconfirmed
Regeneron extends U.S. agreement for additional Ebola treatment supply[8]Regeneron 延长美国埃博拉治疗药物供应协议news.google.com
Reported: 2026-10-26
Regeneron extended a U.S. agreement for additional supply of an Ebola treatment.
2026-10-25
Regeneron presents 44-month Libtayo follow-up data[9]再生元公布 Libtayo 44 个月随访数据econotimes.com
Reported: 2026-10-25
Regeneron presented a 44-month follow-up update on Libtayo in patients with high-risk skin cancer at the European Society for Medical Oncology Congress in Madrid. The reported estimated death hazard ratio was 0.63 versus placebo, but its 95% confidence interval crossed 1.0, so the update did not establish a statistically significant overall-survival advantage.
Unconfirmed
Sanofi expands Regeneron partnership with deal worth up to $8 billion[10]赛诺菲扩大与再生元的合作，交易金额最高达80亿美元news.google.com
Reported: 2026-10-01
Reuters reported that Sanofi expanded its partnership with Regeneron through a deal worth up to $8 billion, described as a win for Sanofi's new chief executive.
2021-11-22
Amgen files Supreme Court petition in patent dispute[4]Amgen files Supreme Court petition in patent disputelawstreetmedia.com
Reported: 2021-11-23
Amgen Inc. and its subsidiaries filed a petition for certiorari with the U.S. Supreme Court against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC. The petition concerns the written-description requirement for patents and the level of detail required.
2021-07-22
Humana sues Regeneron over alleged Eylea pricing scheme[5]Humana sues Regeneron over alleged Eylea pricing schemelawstreetmedia.com
Reported: 2021-07-23
Humana filed suit against Regeneron, alleging that Regeneron and the Chronic Disease Foundation engaged in a scheme involving Eylea that defrauded Medicare and its contracted payors. The complaint alleged that Regeneron inflated Eylea's price and provided illegal kickbacks to the foundation; these are allegations, not a stated court finding.
Unconfirmed
Shareholder advisers criticize Regeneron executive payouts[6]Shareholder advisers criticize Regeneron executive payoutstheguardian.com
Reported: 2021-06-10
Shareholder advisory groups Glass Lewis and Institutional Shareholder Services criticized Regeneron’s upfront executive stock awards as excessive and questioned whether they were in shareholders’ best interests. The article also reports substantial shareholder opposition to the company’s executive payouts in recent years.
2021-02-11
FDA approves Evkeeza for HoFH[11]FDA 批准 Evkeeza 用于治疗 HoFHprnewswire.com
Reported: 2021-02-11
The U.S. Food and Drug Administration approved Regeneron’s Evkeeza as an adjunct to other LDL-C-lowering therapies for adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia.
2021-02-11
FDA approves Regeneron’s evinacumab[12]FDA批准Regeneron的依维卡单抗medcitynews.com
Reported: 2021-02-11
The FDA approved Regeneron’s drug evinacumab as an addition to other cholesterol-lowering therapies for adults and children older than 12 with homozygous familial hypercholesterolemia. The drug will be marketed under the name Evkeeza.
2021-02-09
FDA approves Libtayo for advanced basal cell carcinoma[13]FDA批准Libtayo用于晚期基底细胞癌finanznachrichten.de
Reported: 2021-02-09
The U.S. FDA approved Libtayo for patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom such treatment is not appropriate; approval was full for locally advanced disease and accelerated for metastatic disease.
2020-12-11
Regeneron challenges federal drug-pricing rule[14]再生元起诉挑战联邦药品定价规则lawstreetmedia.com
Reported: 2020-12-11
Regeneron Pharmaceuticals filed a complaint against the Department of Health and Human Services and other federal defendants, challenging a drug-pricing rule and alleging, among other claims, that it was issued without the notice-and-comment period required by the Administrative Procedures Act.

Showing the 10 most recent.

Sources21 sources

Cite this profile: Cite the canonical profile. /brand-wiki/regeneron · Editorial policy · How profiles are compiled

Overview

History

Products and positioning

Controversies

Recent events

Sources21 sources